Allergy and cold
Remibrutinib
Bruton Tyrosine Kinase (BTK) Inhibitor, covalent-irreversible
Other names: Rhapsido
Wait
2 weeks
after the first dose
The FAA's MedGuide lists remibrutinib (Rhapsido) as allowed, for urticaria, with a wait of 2 weeks after the first dose and none after later doses or after the final dose, used as prescribed.
Track your medicationsMore detail: remibrutinibThe rest of Crosscheck's reading, in plain wordsOpen
The MedGuide defines allowed as acceptable for use while performing flight or safety-related duties, provided the condition is stable/aeromedically acceptable and no adverse side effects are present, and says wait times are not determined solely by the medication: an extended observation period may be required to verify clinical stability of the condition.
- 14 days after the first dose: ground observation
Show the FAA's words: remibrutinibThe official FAA wording: three passages, each with its document and dateOpen
Generic: remibrutinib
Brand Name: Rhapsido
Drug Class: Bruton Tyrosine Kinase (BTK) Inhibitor, covalent-irreversible
Underlying Condition: Urticaria
Use: ALLOW
INITIAL Wait Time (after first dose): 2 weeks
SUBSEQUENT Dose Wait Time (after each dose): None
DISCONTINUATION Wait Time (after final dose): None
Frequency Use Limit: As prescribed
ALLOWED: The medication is acceptable for use while performing flight or safety-related duties, provided the condition is stable/aeromedically acceptable and no adverse side effects are present.
Underlying Condition: Evaluating medication use requires considering the impact of safety of flight from both the medication and underlying condition. Wait times are not determined solely by the medication; an extended observation period may be required to verify clinical stability of the condition.